Prior Heart Failure Hospitalization and Outcomes in Patients with Heart Failure with Preserved and Reduced Ejection Fraction - 02/01/20
Abstract |
Background |
A prior hospitalization resulting from heart failure is associated with poor outcomes in ambulatory patients with heart failure. Less is known about this association in hospitalized patients with heart failure and whether it varies by ejection fraction.
Methods |
Of the 25,345 hospitalized patients in the Medicare-linked OPTIMIZE-HF registry, 22,491 had known heart failure, of whom 7648 and 9558 had heart failure with preserved (≥50%) and reduced (≤40%) ejection fraction (HFpEF and HFrEF), respectively. Overall, 927 and 1862 patients with HFpEF and HFrEF had hospitalizations for heart failure during the 6 months before the index hospitalization, respectively. Using propensity scores for prior heart failure hospitalization, we assembled two matched cohorts of 924 pairs and 1844 pairs of patients with HFpEF and HFrEF, respectively, each balanced for 58 baseline characteristics. Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for outcomes during 6 years of follow-up.
Results |
Among 1848 matched patients with HFpEF, HRs (95% CIs) for all-cause mortality, all-cause readmission, and heart failure readmission were 1.35 (1.21-1.50; P <0.001), 1.34 (1.21-1.47; P <0.001), and 1.90 (1.67-2.16; P <0.001), respectively. Respective HRs (95% CIs) in 3688 matched patients with HFrEF were 1.17 (1.09-1.26; P <0.001), 1.32 (1.23-1.41; P <0.001), and 1.48 (1.37-1.61; P <0.001).
Conclusions |
Among hospitalized patients with heart failure, a previous hospitalization for heart failure is associated with higher risks of mortality and readmission in both HFpEF and HFrEF. The relative risks of death and heart failure readmission appear to be higher in HFpEF than in HFrEF.
Le texte complet de cet article est disponible en PDF.Keywords : Heart failure, Mortality, Preserved ejection fraction, Prior hospitalization, Readmission
Plan
| Funding: Dr. Ali Ahmed was in part supported by the National Institutes of Health through grants (R01-HL085561, R01-HL085561-S and R01-HL097047) from the National Heart, Lung, and Blood Institute (NHLBI). OPTIMIZE-HF was sponsored by GlaxoSmithKline, but played no role in the design, conduct, analyses or interpretation of the current study. |
|
| Conflicts of Interest: AM, GSG. FKL, LST, SNS, CJM, RMA, AA report none. GCF consults with Abbott, Amgen, Bayer, Janssen, Medtronic, Novartis, and was the Principal Investigator of OPTIMIZE-HF. This content is solely the responsibility of the authors and does not necessarily represent the official views of the Department of Veterans Affairs. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 133 - N° 1
P. 84-94 - janvier 2020 Retour au numéro
Article précédent
- Predictors of Mortality in Myocardial Infarction and Nonobstructed Coronary Arteries: A Systematic Review and Meta-Regression
- Francesco Pelliccia, Vincenzo Pasceri, Giampaolo Niccoli, Gaetano Tanzilli, Giulio Speciale, Carlo Gaudio, Filippo Crea, Paolo G. Camici
- Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins – Confirmation from PCSK9 Inhibitor Studies
- Tanya Salvatore, Riccardo Morganti, Roberto Marchioli, Raffaele De Caterina
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?